Mpm Bioimpact
$1.3B Assets Reported
49 Holdings
Latest filing 2026-03-31
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| DBVT | DBV Technologies S A | 5,213,361 | $109M | 8.4% |
| CGEM | Cullinan Therapeutics, Inc. | 7,648,268 | $109M | 8.4% |
| AKTS | Aktis Oncology, Inc. | 4,835,872 | $87M | 6.7% |
| LQDA | Liquidia Corporation | 1,405,158 | $53M | 4.1% |
| ALMS | Alumis Inc | 2,386,529 | $53M | 4.1% |
| EWTX | Edgewise Therapeutics Inc | 1,660,696 | $52M | 4.0% |
| RVMD | Revolution Medicines, Inc. | 506,776 | $49M | 3.8% |
| AGIO | Agios Pharmaceuticals Inc | 1,306,261 | $44M | 3.4% |
| CORT | Corcept Therapeutics, Inc. | 985,700 | $40M | 3.1% |
| TRVI | Trevi Therapeutics Inc | 3,298,430 | $39M | 3.0% |
Track Mpm Bioimpact's 13F portfolio: $1.3B in reported holdings, 49 positions. Top holdings, AUM, and quarterly changes on SentiSense.